The PEHO syndrome

Brain Dev. 2001 Nov;23(7):765-9. doi: 10.1016/s0387-7604(01)00283-2.

Abstract

The progressive encephalopathy with edema, hypsarrhythmia, and optic atrophy (PEHO) syndrome is a pediatric disorder of unknown origin, characterized by a combination of postnatally progressive encephalopathy, hypsarrhythmia, and optic atrophy. The pathological findings are early progressive atrophy of the cerebellum, brainstem, and optic nerves. Nitric acid (NO) has recently been implicated in the mechanisms of seizure activity and neurodegeneration, which are both very active in the PEHO syndrome. However, recent studies have provided evidence that insulin-like growth factor 1 (IGF-1) may prevent the NO-mediated neuronal damage and is essential for the survival of the cerebellar granule cells. These cells will degenerate in the PEHO syndrome. In this study, we set out to test the hypothesis that NO production is activated in the PEHO syndrome and that NO production may be correlated with the reduced production of IGF-1 in the brain. Cerebrospinal fluid IGF-1 was determined with an RIA kit and NO metabolites by the Griess calorimetric method. In patients with the PEHO syndrome, as compared with controls, the levels of IGF-1 were reduced and the levels of nitrite/nitrate were markedly elevated. Defective production of IGF-1 probably reflects the underlying neurodegeneration and the increase in NO production probably reflects the seizure activity and/or neurodegeneration. These are the first biochemical abnormalities found in the PEHO syndrome and their study may lead to a better understanding of this devasting disease.

Publication types

  • Review

MeSH terms

  • Brain Diseases / cerebrospinal fluid
  • Brain Diseases / etiology*
  • Brain Edema / cerebrospinal fluid
  • Brain Edema / etiology*
  • Humans
  • Infant
  • Insulin-Like Growth Factor I / cerebrospinal fluid
  • Nitric Acid / cerebrospinal fluid
  • Optic Atrophy / cerebrospinal fluid
  • Optic Atrophy / etiology*

Substances

  • Nitric Acid
  • Insulin-Like Growth Factor I